GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Ending Cash Position

Hualan Biological Engineering (SZSE:002007) Ending Cash Position : ¥1,169 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Ending Cash Position?

Hualan Biological Engineering's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥1,169 Mil.

Hualan Biological Engineering's quarterly Ending Cash Position increased from Sep. 2023 (¥642 Mil) to Dec. 2023 (¥989 Mil) and increased from Dec. 2023 (¥989 Mil) to Mar. 2024 (¥1,169 Mil).

Hualan Biological Engineering's annual Ending Cash Position increased from Dec. 2021 (¥671 Mil) to Dec. 2022 (¥1,097 Mil) but then declined from Dec. 2022 (¥1,097 Mil) to Dec. 2023 (¥989 Mil).

Hualan Biological Engineering Ending Cash Position Historical Data

The historical data trend for Hualan Biological Engineering's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering Ending Cash Position Chart

Hualan Biological Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 602.10 961.81 671.37 1,096.66 989.33

Hualan Biological Engineering Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 724.04 1,063.04 642.22 989.33 1,168.61

Hualan Biological Engineering Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hualan Biological Engineering's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1096.656+-107.331
=989

Hualan Biological Engineering's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=989.326+179.282
=1,169

Hualan Biological Engineering Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Hualan Biological Engineering (SZSE:002007) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Ending Cash Position
Comparable Companies
SZSE:300759 SZSE:002653 SZSE:301301 SZSE:002821 SHSE:688578 SHSE:603233 SHSE:688278 SHSE:688520 SZSE:000403 SZSE:002252 OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
N/A
Address
No. A1 Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Website
http://www.hualanbio.com
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
An Kang Directors, executives
Pan Ruo Wen Executives
An Wen Qi Executives
Wang Qi Ping Directors, executives
Fan Bei Directors, executives
Ma Xiao Wei Executives
Xie Jun Min Directors, executives
Zhang Bao Xian Executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors
Sun Zhen Guo Supervisors
Chen Lei Shan Supervisors
Yang Bao Ping Supervisors

Hualan Biological Engineering (SZSE:002007) Headlines

No Headlines